World Diabetes Day 2026: Six Breakthroughs Redefining Diabetes Treatment 

From triple-hormone agonists and oral GLP-1 therapies to once-weekly insulin and continuous glucose monitoring, 2026 is reshaping the treatment landscape for type 2 diabetes. 

Key Takeaways: What These Breakthroughs Mean for Clinical Development

• Higher efficacy standards: Emerging therapies are raising expectations for clinical outcomes and treatment differentiation.

• Broader endpoints: Beyond HbA1c, trials increasingly assess weight, cardiovascular health, and long-term benefits.

• More targeted patient selection: Disease characteristics and treatment history are becoming critical to clinical outcomes.

• Evolving trial design: Digital monitoring, CGM, and complex treatment regimens require more sophisticated trial operations.

• Focus on lasting benefits: Long-term safety, durability of response, and sustained disease modification remain key priorities.

For decades, treatment of type 2 diabetes focused primarily on lowering blood glucose and preventing complications. Today, clinical development is moving toward a broader objective: achieving substantial weight reduction, improving metabolic health, reducing treatment burden, and potentially altering the course of the disease. 

This shift is supported by major Phase III results, new regulatory approvals, and emerging evidence that earlier intervention can induce diabetes remission in selected patients. 

On World Diabetes Day 2026, we examine six advances that illustrate how diabetes treatment is evolving and what they mean for future clinical research.

Triple-Hormone Agonists: Retatrutide Sets a New Benchmark

GLP-1 receptor agonists have transformed diabetes treatment, but researchers are now investigating whether targeting multiple metabolic pathways simultaneously can deliver greater benefits. 

Retatrutide, Eli Lilly’s investigational triple agonist, activates GIP, GLP-1, and glucagon receptors, combining effects on insulin secretion, appetite regulation, and energy metabolism. 

In the Phase III TRIUMPH-2 trial, involving 1,152 adults with type 2 diabetes and obesity or overweight, retatrutide demonstrated substantial improvements over 80 weeks. 

Key results included: 

• 20.8% average weight reduction with retatrutide 12 mg, compared with 4.0% with placebo. 

• Up to 1.6 percentage points reduction in HbA1c. 

• Up to 40% of participants achieved HbA1c below 5.7%. 

These findings suggest that triple-receptor agonism could substantially expand the therapeutic potential of metabolic treatments. 

However, retatrutide remains investigational. Longer-term safety, tolerability, and the durability of metabolic benefits will be critical to understanding its future clinical role.

Amylin-Based Combination Therapies: Beyond GLP-1 Alone

The next generation of type 2 diabetes treatments is moving beyond glucose control alone. Increasingly, researchers are exploring therapies that simultaneously improve glycemic control, reduce excess body weight, and address the metabolic dysfunction underlying the disease. 

CagriSema, developed by Novo Nordisk, combines semaglutide, a GLP-1 receptor agonist, with cagrilintide, a long-acting amylin analogue. By targeting complementary hormonal pathways, the combination aims to improve glucose regulation while promoting greater weight reduction. 

The Phase III REIMAGINE program is evaluating CagriSema across different type 2 diabetes populations and treatment settings. 

In REIMAGINE 5, CagriSema 1.0 mg/1.0 mg was compared directly with tirzepatide 5 mg in adults whose diabetes remained inadequately controlled on metformin, an SGLT2 inhibitor, or both. 

At 60 weeks: 

• 12.4% weight reduction with CagriSema versus 9.1% with tirzepatide 5 mg. 

• 1.71 percentage points HbA1c reduction with CagriSema versus 1.67 percentage points with tirzepatide. 

CagriSema met the trial’s superiority endpoint for weight reduction and noninferiority endpoint for HbA1c reduction. 

For patients with type 2 diabetes, these findings are particularly relevant because excess body weight contributes to insulin resistance and makes long-term glucose management more challenging. Substantial weight reduction can improve insulin sensitivity, support glycemic control, and reduce cardiometabolic risk factors. 

The results highlight the potential of amylin-based combinations to address both excess body weight and hyperglycemia. However, the trial compared specific doses, and its findings should not be generalized to higher tirzepatide doses. 

Gastrointestinal tolerability, long-term safety, and treatment persistence remain important considerations as these therapies advance through clinical development.

Oral GLP-1 Therapies: A New Competitive Frontier

Injectable GLP-1 therapies have delivered substantial clinical benefits, but oral alternatives could offer greater flexibility for patients who prefer tablets. 

Orforglipron, developed by Eli Lilly, is an oral, nonpeptide GLP-1 receptor agonist that can be taken without the food and water restrictions associated with some peptide-based oral formulations. 

In the Phase III ACHIEVE-3 trial, 1,698 adults with type 2 diabetes inadequately controlled on metformin received orforglipron or oral semaglutide. 

At 52 weeks, the highest evaluated doses produced the following results: 

• HbA1c reduction: 2.2 percentage points with orforglipron 36 mg versus 1.4 percentage points with oral semaglutide 14 mg. 

• Weight reduction: 9.2% versus 5.3%, respectively. 

Orforglipron demonstrated superior glycemic and weight outcomes at the doses studied. 

In April 2026, the FDA approved orforglipron for chronic weight management. Its diabetes development program represents a further opportunity to expand oral metabolic treatment options. 

For clinical development, ACHIEVE-3 also demonstrates the growing importance of active-comparator studies as sponsors seek to establish meaningful differentiation from existing therapies.

Once-Weekly Insulin: From 365 Injections to 52

Not every patient with type 2 diabetes can achieve adequate glycemic control without insulin. For those requiring basal insulin, treatment frequency can significantly affect daily disease management. 

In 2026, two once-weekly basal insulin products received FDA approval for adults with type 2 diabetes. 

• Insulin icodec (Awiqli), developed by Novo Nordisk, became the first FDA-approved once-weekly basal insulin in March 2026. 

• Insulin efsitora alfa (Onswik), developed by Eli Lilly, subsequently received FDA approval in September 2026. 

The QWINT Phase III clinical development program evaluated once-weekly efsitora against daily basal insulin across different patient populations. 

Across four randomized trials, efsitora demonstrated noninferior HbA1c reductions compared with insulin glargine or insulin degludec. 

Moving from daily to weekly basal insulin reduces scheduled basal injections from approximately 365 to 52 annually, a reduction of around 86%. 

While careful dose adjustment, glucose monitoring, and hypoglycemia management remain essential, once-weekly insulin represents a meaningful advance in treatment convenience.

Continuous Glucose Monitoring and AI: Toward More Personalized Diabetes Care

Continuous glucose monitoring (CGM) is increasingly being evaluated beyond patients receiving insulin. The randomized CONNECT trial investigated CGM in 283 adults with type 2 diabetes who were not using insulin, across 22 primary care practices. 

At 26 weeks: 

• HbA1c decreased from 8.8% to 7.2% in the CGM group. 

• HbA1c decreased from 8.7% to 8.0% with routine care. 

• The adjusted between-group difference was 0.9 percentage points in favor of CGM. 

• Time spent within the target glucose range increased by approximately 21 percentage points compared with routine care. 

The results demonstrate that CGM can improve glycemic management even in patients who do not require insulin therapy. 

Artificial intelligence may further extend the value of these technologies. Algorithms capable of analyzing glucose trends alongside medication, nutrition, and activity data could support personalized treatment decisions, earlier identification of deterioration, and more precise monitoring. 

For clinical trials, digital glucose data may also provide more detailed insight into treatment response than periodic laboratory measurements alone.

Early Intervention: New Evidence for Type 2 Diabetes Remission

Perhaps one of the most clinically important developments of 2026 concerns the possibility of achieving remission through early, intensive intervention. 

The randomized RESET for Remission trial enrolled 96 adults aged 18–45 with early-onset type 2 diabetes and obesity. Participants received either usual care or an intensive program combining a low-energy diet with supervised aerobic and resistance exercise. 

At 24 weeks: 

• 54% of participants in the intervention group achieved diabetes remission. 

• Only 4% achieved remission with usual care. 

• The intervention group achieved substantially greater weight and fat reduction. 

Remission was defined as HbA1c below 6.5% without glucose-lowering medication for at least 12 weeks. 

These results demonstrate that early-onset type 2 diabetes can enter remission following intensive lifestyle intervention. 

The findings reinforce the importance of early intervention while highlighting a major unanswered question: how can remission be maintained over time? 

World Diabetes Day 2026: Turning Scientific Progress into Better Outcomes 

World Diabetes Day 2026 is an opportunity to recognize how rapidly diabetes research is advancing and why early intervention, innovation, and access to effective treatment matter more than ever. 

From triple-hormone agonists and amylin-based combinations to oral GLP-1 therapies, once-weekly insulin, and continuous glucose monitoring, recent advances are expanding treatment possibilities. At the same time, new evidence on diabetes remission highlights the potential benefits of intervening earlier in the course of the disease. Yet scientific progress must ultimately be measured by its ability to deliver sustained improvements in patients’ health and quality of life. 

For drug developers, the challenge is to translate these promising advances into safe, effective, and accessible treatments that deliver lasting benefits. 

At Cromos Pharma, we support biotech and pharmaceutical sponsors in bringing innovative therapies through clinical development. 

Developing an innovative diabetes therapy? Connect with Cromos Pharma at inquiry@cromospharma.com to discuss your clinical development strategy.